Original article

Prospects for Use of Ceftolosan-Tazobactam in Providing Medical Care to Victims in a Third-Level Hospital and during Inter-Hospital Medical Evacuation

Download the article in pdf format                                              Download the article English in pdf format

Parvanyan S.G., Shelukhin D.A., Voroshilova T.M.

Nikiforov Russian Centre of Emergency and Radiation Medicine, EMERCOM of Russia, St. Petersburg, Russian Federation

UDC 614.2

Pp. 35–40

Abstract. It is noted that nosocomial infections are a serious threat to the safety of hospital patients due to their high prevalence and high mortality rate. The prospects of using a new antibacterial drug ceftolosan-tazobactam as a starting empirical therapy in patients with a high risk of nosocomial infection caused by multidrug-resistant microorganisms in a level III hospital and during inter-hospital medical evacuation are considered.

Key words: antibiotic resistance, ceftolosan, empirical antibacterial therapy, inter-hospital medical evacuation, level III hospital, nosocomial infection, tazobactam, zerbaxa

For citation: Parvanyan S.G., Shelukhin D.A., Voroshilova T.M. Prospects for Use of Ceftolosan-Tazobactam in Providing Medical Care to Victims in a Third-Level Hospital and during Inter-Hospital Medical Evacuation. Meditsina Katastrof = Disaster Medicine. 2021; 1: 35-40 (In Russ.). https://doi.org/10.33266/2070-1004-2021-1-35-40


1. Gumanenko E.K., Ogarkov P.I., Lebedev V.F., Boyarintsev V.V., Kuzin A.A. Infectious Complications of Polytram. Microbiological and Epidemiological Aspects. Vestnik Khirurgii = Annals of Surgery. 2006; 165; 5: 56-62 (In Russ.).

2. Rud’ A.A. Prognozirovanie, diagnostika i profilaktika infektsionnykh oslozhneniy pri politravmakh = Forecasting, Diagnosing and Preventing Infectious Complications in Polytrams. Candidate’s thesis in Medicine. St. Petersburg Publ., 2008 (In Russ.).

3. Lachiewicz A.M., Hauck C.G., Weber D.J., Cairns B.A., van Duin D. Bacterial Infec-tions after Burn Injuries: Impact of Multidrug Resistance. Clinical Infectious Diseases. 2017; 65; 12: 2130-6.

4. Lebedev V.F. Klinicheskie, epidemiologicheskie i mikrobiologicheskie aspekty posttravmaticheskogo sepsisa = Clinical, Epidemiological and Microbiological Aspects of Post-Traumatic Sepsis. Materialy II s’ezda anesteziologov-reanimatologov Severo-Zapada RF. Arkhangelsk Publ., 2003; 247-248 (In Russ.).

5. Seleznev A.N., Bagnenko S.F., Shapot Yu.B., Kurygin A.A. Travmaticheskaya bolezn i ee oslozhneniya. Rukovodstvo dlya vrachey = Traumatic Disease and its Complications. St. Petersburg Publ., 2004 (In Russ.).

6. Chernen’kaya T.V., Godkov M.A. «Problematic» Polyressive Bacteria are the Pathogens of Hospital-Acquired Infections in Patients in Critical Conditions. Literature review. Zhurnal im. N.V.Sklifosovskogo. Neotlozhnaya meditsinskaya pomoshch. 2015; 3: 30–35 (In Russ.).

7. Yakovlev S.V., Briko N.I. Sidorenko S.V. Protsenko D.N. Programma SKAT strategiya kontrolya antimikrobnoy terapii pri okazanii statsionarnoy meditsinskoy pomoshchi. Metodicheskie rekomendatsii = The SCAT Program Antimicrobial Therapy Control Strategy in the Provision of Inpatient Care. Moscow Publ., 2018 (In Russ.).

8. Strich J.R., Palmore T.N. Preventing Transmission of Multidrug-Resistant Pathogens in the Intensive Care Unit. Infect Dis Clin North Am. 2017; 31; 3: 535-550.

9. Emine A., Nizam D. Healthcare-Associated Infections in Intensive Care Units: Epide-miology and Infection Control in Low-To-Middle Income Countries. The journal of infection in developing countries. 2015; 9; 10: 1040-1045.

10. Kalanuria A.A., Zai W., Mirski M. Ventilator-Associated Pneumonia in the ICU. Criti-cal Care. 2014; 18: 208.

11. Yakovlev S.V., Suvorova M.P. Nosocomial urinary tract infections. Urologiya. 2016; 3; 3: 43-62 (In Russ.).

12. Van Nieuwkoop C., Bonten T.N., Van’t Wout J.W. Risk Factors for Bacteremia with Uropathogen not Cultured from Urine in Adults with Febrile Urinary Tract Infection. Clin. In-fect. Dis. 2010; 50: 69-72.

13. Horcajada J.P., Shaw E., Padilla B. Healthcare-Associated, Community-Acquired and Hospital-Acquired Bacteraemic Urinary Tract Infections in Hospitalized Patients: a Prospective Multicenter Cohort Study in the Era of Antimicrobial Resisatnce. Clin. Microbiol. Infect. 2013; 19: 962-968.

14. Goodlet K.J., Nicolau D.P., Nailor M.D. Ceftolozane/tazobactam and Ceftaz-idime/Avibactam for the Treatment of Complicated Intra-Abdominal Infections. Therapeutics and Clinical Risk Management. 2016; 12: 1811-1826.

15. Sartelli M., Chichom-Mefire A., Labricciosa F.M. et al. The Management of Intra-Abdominal Infections from a Global Perspective: 2017 WSES guidelines for management of in-traabdominal infections. World Journal of Emergency Surgery. 2017; 12:29.

16. Mulani M.S., Kamble E.E., Kumkaret S.N. et al. Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance. Frontiers in Microbiology. April 2019; 10: 539.

17. Founou R.C., Founou L.L., Essack S.Y. Clinical and Economic Impact of Antibiotic Resistance in Developing Countries: a Systematic Review and Meta-Analysis. PLoS One. 2017, Dec. 21; 12; 12: e0189621. https://doi.org/10.1371/journal.pone.0189621

18. Tacconelli E., Carrara E., Savoldi A. et al. Discovery, Research, and Development of New Antibiotics: the Who Priority List of Antibiotic-Resistant Bacteria and Tuberculosis. Lancet Infect. Dis. 18: 318–327.

19. Vincent J.L., Rello J., Marshall J. et al. International Study of the Prevalence and Out-comes of Infection in Intensive Care Units. JAMA. 2009; 302; 21: 2323-2329.

20. Santayit S., Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed. Res. Int. 2016; 2016; 2475067.

21. Jacoby G.A., Munoz-Price L.S. The New Beta-Lactamases. NEJM. 2005; 352; 4: 380-391.

22. Giedraitiene A., Vitkauskiene A., Nagniene R., Pavilonis A. Antibiotic Resistance Mechanisms of Clinical Important Bacteria. Medicina (Kaunas). 2011; 47; 3: 137-46.

23. Wright G.D. Bacterial Resistance to Antibiotics: Enzymatic Degradation and Modifica-tion. Advanced drug delivery reviews. 2005; 57; 10: 1451-1470.

24. Scweizer H.P. Efflux as a Mechanism of Resistance to Antimicrobials in Pseudomonas Aeruginosa and Related Bacteria: unanswered questions. Genetics and molecular research. 2003; 2; 1: 48-62.

25. Laverty. G., Gorman S.P., Gilmore B.F. Biomolecular Mechanisms of Pseudomonas Aeruginosa and Escherichia Coli Biofilm Formation. Pathogens. 2014; 3; 3: 596-623.

26. Shaydullina E.R., Eydelshteyn M.V., Skleenova E.Yu., Sukhorukova M.V., Kozlov R.S. Antibiotic resistance of nosocomial carbapenemazoduducing strains Enterobacterales in Russia: results of epidemiological study 2014-2016. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2018; 20; 4: 362-369 (In Russ.).

27. Karaiskos I., Giamarellou H. Carbapenem-Sparing Strategies for ESBL Producers: when and how. Antibiotics. 2020; 9: 61.

28. Sebaaly J., Woods J.A., Wargo K.A. A Review of Ceftolozane/Tazobactam for the Treatment of Infections Caused by Multidrug-Resistant Pathogens. Infectious Diseases in Clini-cal Practice. 2018; 26; 4.

29. Giacobbe D.R. Bassetti M., De Rosa F.G. et al. Ceftolozane/Tazobactam: Place in Therapy. Expert Review of Anti-infective Therapy. ISSN: 1478-7210.

30. Zhanel G.G., Chang. P., Adam H. et al. Ceftolozane/Tazobactam: A Novel Cepha-losporin/b-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli Drugs. 2014; 74: 31-51.

31. Chandorkar G., Huntington J.A., Gotfried M.H. et al. Intrapulmonary Penetration of Ceftolozane/Tazobactam and Piperacillin/Tazobactam in Healthy Adult Subjects. J. Antimicrob. Chemother. 2012; Oct; 67; 10: 2463-9.

32. Caro L., Larson K., Nicolau D. Lung Penetration and PK/PD Attainment in Pulmonary Epithelial Lining Fluid (ELF) Following 3 g Administration of Ceftolozane/Tazobactam (TOL/TAZ) to Ventilated, Critically-Ill Patients. 28th Annual European Congress of Clinical Microbiology and Infectious Diseases; Madrid, Spain; April 21–24, 2018. abstr P2225.

33. Xiao A.J., Miller B.W., Huntington J.A., Nicolau D.P. Ceftolozane/Tazobactam Phar-macokinetic/Pharmacodynamic-Derived Dose Justification for Phase 3 Studies in Patients with Nosocomial Pneumonia. J Clin Pharmacol. 2016; Jan; 56; 1: 56-66.

34. Instructions on the medical use of the drug Zerbax. Ministry of Health of the Rissian Federation dated October 31, 2019. No. 005085 (In Russ.).

35. Lindberg O., De Geer L., Chew M.S. Nonadherence to Antibiotic Guidelines in Pa-tients Admitted to ICU with Sepsis is Associated with Increased Mortality: A registry-based, ret-rospective cohort study. Eur J Anaesthesiol. 2020; Feb; 37; 2: 113-120.

36. Dyakov I.N., Zyryanov S.K., Khachatryan N.N. Pharmacoeconomic evaluation of the use of the drug cephtolazane + tazobactam in the treatment of complicated nosocomial intraabdominal infections. Kachestvennaya Klinicheskaya Praktika. 2019; 2: 55-68 (In Russ.).

The material was received 09.07.20; the article after peer review procedure 09.09.20; the Editorial Board accepted the article for publication 30.11.20